Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 11 04:00PM ET
5.37
Dollar change
-0.29
Percentage change
-5.12
%
Index- P/E- EPS (ttm)-19.33 Insider Own14.02% Shs Outstand1.25M Perf Week-6.77%
Market Cap7.07M Forward P/E- EPS next Y-16.03 Insider Trans0.00% Shs Float1.13M Perf Month-24.15%
Income-21.17M PEG- EPS next Q-2.82 Inst Own2.18% Short Float1.79% Perf Quarter-62.05%
Sales0.00M P/S- EPS this Y56.79% Inst Trans-33.10% Short Ratio0.66 Perf Half Y-59.48%
Book/sh16.70 P/B0.32 EPS next Y-2.82% ROA-57.67% Short Interest0.02M Perf Year-64.62%
Cash/sh14.95 P/C0.36 EPS next 5Y47.60% ROE-72.61% 52W Range5.30 - 23.50 Perf YTD-70.17%
Dividend Est.- P/FCF- EPS past 5Y-14.07% ROI-101.14% 52W High-77.15% Beta1.14
Dividend TTM- Quick Ratio8.68 Sales past 5Y0.00% Gross Margin- 52W Low1.32% ATR (14)0.42
Dividend Ex-Date- Current Ratio8.68 EPS Y/Y TTM56.12% Oper. Margin- RSI (14)31.66 Volatility5.40% 6.35%
Employees13 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price10.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q54.81% Payout- Rel Volume0.72 Prev Close5.66
Sales Surprise- EPS Surprise8.38% Sales Q/Q- EarningsNov 01 BMO Avg Volume30.76K Price5.37
SMA20-7.80% SMA50-21.62% SMA200-58.99% Trades Volume22,074 Change-5.12%
Date Action Analyst Rating Change Price Target Change
Apr-26-21Resumed Credit Suisse Outperform $12
Nov-23-20Initiated SVB Leerink Outperform $27
Nov-23-20Initiated Credit Suisse Outperform $29
Nov-23-20Initiated BofA Securities Buy $21
Nov-14-24 09:55AM
Nov-01-24 08:30AM
Oct-18-24 08:15AM
Oct-15-24 08:30AM
Oct-07-24 08:45AM
09:00AM Loading…
Aug-28-24 09:00AM
Aug-12-24 10:53PM
May-03-24 10:54AM
May-01-24 04:01PM
Mar-15-24 01:53PM
Feb-14-24 12:00PM
Jan-09-24 04:57PM
Dec-22-23 06:52AM
Dec-21-23 04:05PM
Oct-23-23 08:00AM
09:49AM Loading…
Sep-28-23 09:49AM
Sep-27-23 05:08AM
Sep-26-23 04:01PM
Aug-31-23 11:00AM
Aug-17-23 07:01PM
08:58AM
Aug-16-23 07:46AM
Aug-15-23 07:35AM
07:30AM
Jul-31-23 04:05PM
Jul-27-23 11:02PM
Jul-25-23 09:59AM
Jun-20-23 08:58AM
May-30-23 08:00AM
May-23-23 08:30AM
08:54AM Loading…
May-20-23 08:54AM
May-17-23 04:01PM
Apr-28-23 08:00AM
Apr-13-23 08:30AM
Mar-09-23 07:00AM
Mar-02-23 04:05PM
Feb-01-23 08:00AM
Dec-11-22 07:36AM
Dec-07-22 04:05PM
Nov-24-22 09:55AM
Nov-11-22 12:00PM
Nov-08-22 09:15AM
06:00AM
Nov-03-22 08:00AM
Oct-31-22 08:00AM
Oct-19-22 08:00AM
Oct-17-22 06:00AM
Sep-29-22 11:17AM
06:00AM
Sep-06-22 08:30AM
Aug-29-22 08:30AM
Jul-29-22 09:00AM
Jul-03-22 08:17AM
Jun-16-22 08:00AM
May-31-22 08:30AM
May-26-22 08:30AM
May-02-22 08:30AM
Apr-29-22 08:57AM
Apr-26-22 08:30AM
Mar-29-22 08:30AM
Mar-25-22 10:25AM
Mar-15-22 11:10AM
Mar-10-22 11:05AM
Mar-09-22 10:49AM
Mar-04-22 10:00AM
Feb-17-22 05:00PM
Feb-07-22 08:00AM
Jan-27-22 07:00AM
Jan-24-22 05:56AM
Jan-19-22 09:38PM
Jan-05-22 08:00AM
Dec-20-21 08:00AM
Dec-13-21 08:00AM
Nov-04-21 04:30PM
Nov-02-21 11:26AM
08:00AM
01:14AM
Oct-28-21 08:00AM
Oct-26-21 08:00AM
Sep-15-21 08:30AM
Sep-13-21 08:00AM
Aug-18-21 09:25AM
08:00AM
Aug-05-21 08:30AM
Jul-28-21 04:31AM
Jul-13-21 08:00AM
Jun-22-21 12:40PM
09:27AM
Jun-10-21 03:31PM
Jun-02-21 08:00AM
May-11-21 08:00AM
May-06-21 08:00AM
May-04-21 08:30AM
Apr-29-21 05:49AM
Apr-19-21 06:38AM
Apr-15-21 08:00AM
Mar-29-21 08:30AM
Mar-23-21 10:26AM
08:30AM
Mar-15-21 07:30AM
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3, lysyl oxidase-like 2, and LOXL2. The company was founded by Ulf Jorgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgard Schambye in 2011 and is headquartered in Boston, MA.